---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-025737"
form_type: "8-K/A"
ticker: "PTIX"
cik: "0001022899"
company_name: "Protagenic Therapeutics, Inc.new"
filed_at: "2025-08-28T23:59:59+00:00"
generated_at: "2026-05-17T09:22:57.389552+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Protagenic restructures after Phytanix acquisition; CEO/COO out, targets $8M savings

## Summary
- Acquired Phytanix Bio on May 15, 2025 via share exchange; gained five preclinical candidates (PHYX-001 to -005).
- On Aug 8, Board approved restructuring: suspended preclinical programs, terminated CEO Barrett Evans and COO Colin Stott.
- Restructuring expected to cut annual operating expenses by ~$8M; focus on Phase 2 trial of PT00114.
- Changed auditor from MaloneBailey to GreenGrowth CPAs; fiscal year changed from Dec 31 to March 31, effective Aug 7, 2025.
- Historical Phytanix loss from ops $2.6M for year ended Mar 31, 2025; cash used in ops $1.8M; ~$1M ATM capacity remains.

## SEC filing metadata
- accession: 0001641172-25-025737
- form_type: 8-K/A
- ticker: PTIX
- cik: 0001022899
- company_name: Protagenic Therapeutics, Inc.new
- filed_at: 2025-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022899/000164117225025737/0001641172-25-025737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022899/000164117225025737/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-025737
- JSON: https://secwatch.observer/filing/0001641172-25-025737.json
- Plain text: https://secwatch.observer/filing/0001641172-25-025737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.